Human tumours have been shown to have widespread changes in the patterns of DNA methylation, showing regional hypermethylation at CpG islands accompanied by global hypomethylation (Lengauer, 2003) . It is known that inhibition of DNA methylation through reduction of DNA methyltransferase 1 (DNMT1) (Laird et al., 1995; Eads et al., 2002) or perturbation of a protein that interprets the DNA methylation signal through knockout of Mbd2, suppresses intestinal tumorigenesis in Apc Min/ þ mice (Sansom et al., 2003) . However, recent murine studies have raised concerns about the effects of proposed antitumour strategies that reduce DNMT1 as global genomic hypomethylation has been shown to induce lymphomas with increased genomic instability Gaudet et al., 2003) . The relevance of these finding to treatment of human cancers is uncertain, as the degree of hypomethylation produced by the hypomorphic allele concerned (DNMT1 chip ) is far greater than following treatment with DNA methylation inhibitors such as 5-aza-2 0 -deoxycytidine or other previously reported DNMT1 hypomorphic alleles (DNMT R and DNMT S ) (Trinh et al., 2002; Eden et al., 2003; Gaudet et al., 2003; Yang et al., 2003) . However, all of the DNMT1 hypomorphic alleles tested thus far have shown increased lymphomagenesis either alone (DNMT chip/ ) or when crossed to mismatch repair deficient Mlh1 À/À mice (DNMT N and DNMT R ) (Trinh et al., 2002) . Given these adverse effects of DNMT1 inhibition and the strong suppression of intestinal tumorigenesis by Mbd2, we have tested whether inhibition of Mbd2 (which is thought to interpret rather than maintain DNA methylation) also accelerates lymphomagenesis.
Loss of Mbd2 does not accelerate p53-mediated lymphomagenesis

Unlike DNMT1
À/À and DNMT N/N (which are lethal), and DNMT chip/À mice (which are runted), Mbd2 À/À mice are apparently healthy (Li et al., 1992; Hendrich et al., 2001; Trinh et al., 2002; Gaudet et al., 2003) . To address whether the loss of Mbd2 accelerated lymphomagenesis, we intercrossed Mbd2 deficient mice to p53 deficient mice (Sansom and Clarke, 2000) . p53 deficiency is the most studied murine model of lymphomagenesis, and unlike MMR deficiency does not induce intestinal tumorigenesis (Trinh et al., 2002) . Therefore, the potential confounding problem caused by suppression of tumorigenesis in one organ and acceleration in another was avoided.
Cohorts of at least 18 Mbd2 þ / þ p53 À/À and Mbd2 À/À p53 À/À mice were aged until they showed signs of disease. Given that we have previously shown a dose-dependent reduction in intestinal tumorigenesis afforded by Mbd2 deficiency (Sansom et al., 2003) , cohorts of mice heterozygous for Mbd2 null allele were also examined (Mbd2
). Figure 1a shows a Kaplan-Meier plot of survival for
and Mbd2
mice. No significant differences were observed in survival between the three different cohorts of at least 18 mice (all statistical analyses, PX0.7, Log rank). We next analysed the tumour spectra and frequency of each tumour type to assess whether there was increased lymphomagenesis in doubly mutant Mbd2
À/À mice died predominantly of lymphoma (Sansom and Clarke, 2000) . However, there was no significant difference between the different genotypes with 83% (15/18) of Mbd2
. Histological analysis of the tumours revealed no clear genotype dependent differences. Thus, in both single and double null mice, thymic lymphomas predominated (63 and 67% respectively), with a reduced number of lymphomas having extra-thymic origin (22 and 17% respectively). In the Mbd2
, the majority of sarcomas (67%) were poorly differentiated, although one was identified as a haemangiosarcoma and one an Figure 1 (a) Deficiency of Mbd2 does not alter survival of p53 deficient mice. Mbd2 and p53 mutant animals were derived from a colony segregating for Ola/129 and C57BL6J genomes, which had been backcrossed three generations onto the C57BL6J background and so were predominantly (87.5%) C57/BL6J. Mice were genotyped by PCR as previously described (Toft et al., 2002; Sansom et al., 2003) . Cohorts of at least 18 mice were monitored and harvested when they exhibited symptoms of disease. Kaplan-Meier plot of survival for Mbd2
No differences in survival were observed between any of the genotypes (PX0.7, Log rank). (b) Mbd2 does not alter tumour distribution in p53 deficient mice. Pie charts of tumour distribution in (a) Mbd2
These pie charts indicate the tumour burden identified at death in each mouse. Grey slice, mice with lymphoma; white slice, mice with sarcoma; black slice, mice with concurrent lymphoma and sarcoma. No significant difference was observed in lymphomagenesis with 23/27 Mbd2 þ / þ p53 À/À developing lymphoma (two of these also had concurrent sarcoma) compared to 15/18 Mbd2 À/À p53 À/À mice (PX0.8 w 2 ). No significant difference was observed in sarcoma either with 6/27 Mbd2 þ / þ p53 À/À developing sarcoma compared to 3/18 Mbd2 À/À p53 À/À mice. (c) Deficiency of Mbd2 does not alter survival of mice heterozygous for p53. Kaplan-Meier plot of survival for Mbd2
No differences in survival were observed between any of the p53 þ /À genotypes (PX0.8, w 2 ). All experiments were performed according to UK Home Office regulations MBD2 deficiency does not accelerate lymphomagenesis O James Sansom et al osteosarcoma, both of which have previously been reported in p53 À/À mice. All three of the sarcomas developing in the Mbd2
À/À were poorly differentiated. These data therefore consolidates the survival data, showing that loss of Mbd2 does not accelerate p53 mediated lymphomagenesis.
Given the strong predisposition to lymphomagenesis and genomic instability associated with p53 deficiency, any effect of Mbd2 deficiency may be masked. We therefore examined the effect of Mbd2 deficiency upon survival of p53 heterozygous mice (Figure 1c) . At 450 days there were no difference in survival between p53
þ / þ mice (42%, 9/21) and p53
À/À (6/15, 40%, P>0.8 w 2 ). In support of our previous studies we again saw no increase in lymphomagenesis in Mbd2 À/À alone (n ¼ 5) at least in mice up to 500 days (Hendrich et al., 2001; Sansom et al., 2003) . These studies in conjunction with our previous studies showing no gross changes in methylation days (Hendrich et al., 2001; Sansom et al., 2003) highlight that complete depletion of Mbd2 does not mimic the effects of the DNMT1 chip/À hypomorph, namely increased tumorigenesis and genomic instability Gaudet et al., 2003) . Therefore, although Mbd2 deficiency fails to suppress lymphomagenesis, critically it does not accelerate neoplasia, even within the highly tumour prone p53 null environment. This finding, coupled with the ability of Mbd2 to suppress intestinal malignancy, enhances the potential of MBD2 as a target for clinical intervention. Indeed, recent studies have shown that depletion of Mbd2 using antisense inhibitors suppresses growth of human lung and colorectal cell lines in vitro and human cancer xenografts in vivo (Campbell et al., 2004) . Therefore, by focussing on the proteins that interpret methylation rather that inhibiting the methylation per se, future antitumour strategies may avoid the possible side effects of global hypomethylation and genomic instability.
